Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
about
Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-AnalysisCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaMarkov modeling in hepatitis B screening and linkage to carePostpartum care for mothers diagnosed with hepatitis B during pregnancy.Medical training fails to prepare providers to care for patients with chronic hepatitis B infection.Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation.Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.T-cell immunoglobulin mucin-3 as a potential inducer of the epithelial-mesenchymal transition in hepatocellular carcinoma.Monitoring and treatment of inactive chronic hepatitis B: is it cost-effective?miR-431-5p alters the epithelial-to-mesenchymal transition markers by targeting in hepatoma cells
P2860
Q26782748-A8B7BB1D-5789-4B15-BC0E-3B06DB2DF48FQ28550643-9A50D623-6298-4620-B2F2-8D01249D6AC9Q33706787-697190C9-2FDE-49F7-9167-71CE74138A1BQ35137366-4875240C-8DD5-4A78-9A39-80D3EB5F7204Q35716226-6085108E-460D-4C7F-9A3E-1074F0AA41D2Q36336005-07ED3C48-A645-4DC0-A0D4-6E32619C6867Q38755073-018D6C5B-4AD8-4DF6-AA24-FB9C9759775AQ39099698-B7CC522C-A965-4C3F-A64C-1FEB332A1DB6Q40303523-CD895B98-7861-42DF-839D-C059B9BA279EQ40400182-30FEF418-46AF-4CB3-BDA8-4372BCB4DC01Q40679543-7521A2AF-D6AE-4ECF-AAE0-F70ABAD8C4E2Q46794523-2E5200BB-905C-40D8-AB0C-0AFA6BD5D459Q51850309-1DE0A5EA-E635-45C6-A889-9A43C607D340Q57483937-585DB124-430B-4638-B68D-9410A99264AF
P2860
Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Population health impact and c ...... e patients in Shanghai, China.
@en
Population health impact and c ...... e patients in Shanghai, China.
@nl
type
label
Population health impact and c ...... e patients in Shanghai, China.
@en
Population health impact and c ...... e patients in Shanghai, China.
@nl
prefLabel
Population health impact and c ...... e patients in Shanghai, China.
@en
Population health impact and c ...... e patients in Shanghai, China.
@nl
P2093
P2860
P356
P1433
P1476
Population health impact and c ...... e patients in Shanghai, China.
@en
P2093
Honglian Gui
Jan Hendrik Richardus
Jiangshe Wang
Mehlika Toy
P2860
P356
10.1002/HEP.26934
P407
P577
2014-05-27T00:00:00Z